Strides Pharma Science Board of Directors

Get the latest insights into the leadership at Strides Pharma Science. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Arun Kumar Non Executive Chairperson
Mr. Ameet Hariani Non Executive Chairperson
Mr. Badree Komandur Managing Director & Group CEO
Mr. Aditya Kumar Executive Director
Dr. Kausalya Santhanam Independent Director
Mr. Homi Rustam Khusrokhan Independent Director
Mr. Subir Chakraborty Independent Director
Ms. Mukta Arora Independent Director

Strides Pharma Science Share price

STAR

896.7

33.00 (3.82%)
NSE
BSE
Last updated on 1 Sep, 2025 | 15:59 IST
BUYSELL
Today's High

914.45

Today's Low

864.00

52 Week Low

513.05

52 Week High

1675.00

The current prices are delayed, login to your account for live prices

Strides Pharma Science FAQs

The board at Strides Pharma Science consists of experienced professionals, including Mr. Arun Kumar , Mr. Ameet Hariani , and others, overseeing the company’s strategic and corporate governance.

Directors at Strides Pharma Science are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Arun Kumar is the current chairman at Strides Pharma Science.

Executive directors at Strides Pharma Science are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Strides Pharma Science adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Strides Pharma Science, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.